Incyte reveals promising trial data for essential thrombocythemia treatment Company News Published 06/03/2025, 10:37 AM 0 ...

While extreme thrombocytosis is known to be associated with a higher risk of bleeding and thrombotic events in patients with essential thrombocythemia (ET), patients with MF typically exhibit ...

Essential thrombocythemia is classified as a chronic myeloproliferative disorder characterized by the overproduction of platelets stemming from a megakaryocytic clone. The diagnosis primarily relies ...

Abstract and Polycythemia Vera and Essential Thrombocythemia: 'Classic' Chronic Myeloproliferative Disorders Perspectives for the Development of Molecularly Targeted Therapy for PV or ET ...

Topline data were announced from a phase 3 trial evaluating ropeginterferon alfa-2b-njft in patients with essential thrombocythemia.

To the Editor: The treatment of symptomatic thrombocythemia is an unresolved problem of hematology and demands rapid action. Both alkylating agents and radioactive phosphorus require days to act, ...

The Shorespan-007 trial will investigate the new drug among patients with essential thrombocythemia who have not previously received cytoreductive therapy.

Case report: Effectiveness of low-dose methotrexate monotherapy in post-essential thrombocythemia myelofibrosis Sebastian Francis 1 Tom King 2 Martin P. Zeidler 3 * ...

Citation: Francis S, King T and Zeidler MP (2024) Case report: Effectiveness of low-dose methotrexate monotherapy in post-essential thrombocythemia myelofibrosis.

The incidence of essential thrombocytosis is 0.6–2.5 per 100,000 5. According to the World Health Organization guidelines, the persistent diagnosis of essential thrombocythemia requires a platelet ...

Dr Naveen Pemmaraju discusses the current treatment standards for both polycythemia vera and essential thrombocythemia, highlighting the needs of high-risk patients.